This is a Phase IV, open-label, single-center, proof-of-concept, pilot study to evaluate the effect of Lactibiane ToleranceĀ® in treating leaky gut in IBS-D patients. 30 consecutive patients with IBS-D and an increased intestinal permeability assessed by 51Cr-EDTA or 99mTc-DTPA will receive the multistrain probiotic Lactibiane ToleranceĀ® 10 billion CFU 1 capsule twice a day (30 minutes before breakfast and 30 minutes before dinner) for 30 days treatment. At the end of treatment, patients will repeat intestinal permeability assessment by 51Cr-EDTA or 99mTc-DTPA.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Proportion of subjects with normal intestinal permeability assessed by 51Cr-EDTA or 99mTc-DTPA
Timeframe: 30 days